We’re excited to support PulseSight Therapeutics in advancing its non-viral vectorized technology, designed to protect and improve vision for patients with retinal diseases. This Series A funding will enable the company to conduct a Phase I study for its lead program, PST-611—a first-in-class, non-viral vectorized therapy targeting dry age-related macular degeneration (AMD) and geographic atrophy (GA). Looking forward to the impact this novel treatment could have on patients suffering from vision loss! https://lnkd.in/e33S3yQ8
Managing Partner at Pureos Bioventures
1moWe are very excited to help the PulseSight team to get 611 into the clinic. Go get em, tiger!